Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E L Simpson

Showing results (61-70 of 100) with videos related to

Pageof 10
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|September 7, 2020
A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacyA S Paller, E C Siegfried, E L Simpson, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 19, 2024
The Eczema Area and Severity Index: An update of progress and challenges in its measurement of atopic dermatitis after 20 years of useM E Jacobson, R Y Morimoto, Y A Leshem, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 14, 2020
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trialsT Bieber, J P Thyssen, K Reich, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 29, 2023
Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristicsJ P Thyssen, D Thaçi, T Bieber, et al.
The British Journal of Dermatology|October 1, 2020
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)A Wollenberg, A Blauvelt, E Guttman-Yassky, et al.
The British Journal of Dermatology|January 30, 2020
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trialsE L Simpson, J-P Lacour, L Spelman, et al.
The British Journal of Dermatology|March 10, 2019
Conjunctivitis in dupilumab clinical trialsB Akinlade, E Guttman-Yassky, M de Bruin-Weller, et al.
The British Journal of Dermatology|July 2, 2014
Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)J R Chalmers, J Schmitt, C Apfelbacher, et al.
Physical Review Letters|April 11, 2025
Search for Dark Matter Produced in Association with a Dark Higgs Boson in the bb[over ¯] Final State Using pp Collisions at sqrt[s]=13  TeV with the ATLAS DetectorG Aad, E Aakvaag, B Abbott, et al.
Physical Review Letters|January 29, 2025
Simultaneous Unbinned Differential Cross-Section Measurement of Twenty-Four Z+jets Kinematic Observables with the ATLAS DetectorG Aad, E Aakvaag, B Abbott, et al.
Pageof 10

Showing results (61-70 of 100) with videos related to

Sort By:
Pageof 10
Journal of the European Academy of Dermatology and Venereology : JEADV|September 7, 2020
A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacyA S Paller, E C Siegfried, E L Simpson, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 19, 2024
The Eczema Area and Severity Index: An update of progress and challenges in its measurement of atopic dermatitis after 20 years of useM E Jacobson, R Y Morimoto, Y A Leshem, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 14, 2020
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trialsT Bieber, J P Thyssen, K Reich, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 29, 2023
Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristicsJ P Thyssen, D Thaçi, T Bieber, et al.
The British Journal of Dermatology|October 1, 2020
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)A Wollenberg, A Blauvelt, E Guttman-Yassky, et al.
The British Journal of Dermatology|January 30, 2020
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trialsE L Simpson, J-P Lacour, L Spelman, et al.
The British Journal of Dermatology|March 10, 2019
Conjunctivitis in dupilumab clinical trialsB Akinlade, E Guttman-Yassky, M de Bruin-Weller, et al.
The British Journal of Dermatology|July 2, 2014
Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)J R Chalmers, J Schmitt, C Apfelbacher, et al.
Physical Review Letters|April 11, 2025
Search for Dark Matter Produced in Association with a Dark Higgs Boson in the bb[over ¯] Final State Using pp Collisions at sqrt[s]=13  TeV with the ATLAS DetectorG Aad, E Aakvaag, B Abbott, et al.
Physical Review Letters|January 29, 2025
Simultaneous Unbinned Differential Cross-Section Measurement of Twenty-Four Z+jets Kinematic Observables with the ATLAS DetectorG Aad, E Aakvaag, B Abbott, et al.
Pageof 10